Cervical Large Cell Neuroendocrine CarcinomaNeCTuRNCT04723095
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
An observational study of Cervical Large Cell Neuroendocrine Carcinoma and Cervical Neuroendocrine Carcinoma, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma
- What is being tested?
- Follow-Up and Medical Chart Review
- How many people
- 750 participants
- Where
- 1 siteUnited States
- Study dates
- 16 May 2013to 1 Jan 2044
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with neuroendocrine cervical cancer
Who may be able to join
- Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:
- Small cell neuroendocrine carcinoma
- Large cell neuroendocrine carcinoma
- Undifferentiated high-grade neuroendocrine carcinoma
- Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
- Patients with all stages of disease are considered eligible
Show all 12Show fewer
- Patients who do not speak English can be eligible if accompanied by an institutional interpreter
- Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
- Patient may be residents of any country and be of any ethnic background
- Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website
- Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate
- Next of kin or legal authorized representatives of patients must read and speak English
Who cannot join
- Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
M D Anderson Cancer Center
Houston, Texas, 77030
Larissa A. Meyer, MD, 713-745-0973, lmeyer@mdanderson.org
Larissa A. Meyer, MD
About this study
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.
Read the detailed description
PRIMARY OBJECTIVES:
- To collect, both prospectively and retrospectively, data on disease characterization, treatment, and outcomes for patients with neuroendocrine carcinoma of the uterine cervix.
II. To organize clinical information in order to support multifaceted queries of patient characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with patient outcome.
III. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.
OUTLINE:
Patients' medical records are reviewed retrospectively and prospectively. All prospective patients will be contacted via email, telephone, or U.S. Mail on case by case basis for up to 10 years to check status of disease and any further treatment received. Project staff can also access the patient's M. D. Anderson Epic medical record for updates. Request for additional clinic and treatment notes will be submitted to external medical institutions listed in the physician information form in order to access updated notes for non- M. D. Anderson patients
- Conditions
- Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8
- Being tested
- Follow-Up, Medical Chart Review
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Follow-UpOther
Also called Active Follow-up, Clinical Signs Follow-up, CLSFUP, Follow Up
Receive follow up
Medical Chart ReviewOther
Also called Chart Review
Review of medical records
| Study group | Role | What they receive |
|---|---|---|
| Observational (medical chart review) | Patients' medical records are reviewed retrospectively and prospectively. All prospective patients will be contacted via email, telephone, or U.S. Mail on case by case basis for up to 10 years to check status of disease and any further treatment received. Project staff can also access the patient's M. D. Anderson Epic medical record for updates. Request for additional clinic and treatment notes will be submitted to external medical institutions listed in the physician information form in order to access updated notes for non- M. D. Anderson patients. Receives: Other: Follow-Up; Other: Medical Chart Review |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease characterization data
Information collected from retrospective and prospective review of medical records.
Measured: through study completion, an average of 1 year
Patient treatment data
Information collected from retrospective and prospective review of medical records.
Measured: through study completion, an average of 1 year
Patient outcome data
Information collected from retrospective and prospective review of medical records.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2021
- Study start16 May 2013
- Primary completion1 Jan 2044 (estimated)
- Study completion1 Jan 2044 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical Large Cell Neuroendocrine CarcinomaStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 750 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Larissa A. Meyer, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04723095
- Sponsor's protocol ID
- PA12-1006
- Other IDs
- NCI-2020-07408, PA12-1006
- Acronym
- NeCTuR
- Status last verified
- Sep 2026
- First submitted
- 13 Oct 2020
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
- ClinicalTrials.gov ID
- NCT04723095
- Acronym / sponsor ID
- NeCTuR / PA12-1006
- Conditions
- Cervical Large Cell Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Cervical Small Cell Carcinoma, Cervical Undifferentiated Carcinoma, Stage I Cervical Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 750 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 16 May 2013 (actual)
- Primary completion
- 1 Jan 2044 (estimated)
- Study completion
- 1 Jan 2044 (estimated)
- First posted
- 25 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.
Detailed description
PRIMARY OBJECTIVES:
- To collect, both prospectively and retrospectively, data on disease characterization, treatment, and outcomes for patients with neuroendocrine carcinoma of the uterine cervix.
II. To organize clinical information in order to support multifaceted queries of patient characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with patient outcome.
III. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.
OUTLINE:
Patients' medical records are reviewed retrospectively and prospectively. All prospective patients will be contacted via email, telephone, or U.S. Mail on case by case basis for up to 10 years to check status of disease and any further treatment received. Project staff can also access the patient's M. D. Anderson Epic medical record for updates. Request for additional clinic and treatment notes will be submitted to external medical institutions listed in the physician information form in order to access updated notes for non- M. D. Anderson patients
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational (medical chart review) | – | Other: Follow-Up, Other: Medical Chart ReviewPatients' medical records are reviewed retrospectively and prospectively. All prospective patients will be contacted via email, telephone, or U.S. Mail on case by case basis for up to 10 years to check status of disease and any further treatment received. Project staff can also access the patient's M. D. Anderson Epic medical record for updates. Request for additional clinic and treatment notes will be submitted to external medical institutions listed in the physician information form in order to access updated notes for non- M. D. Anderson patients. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with neuroendocrine cervical cancer
Key inclusion criteria (12 listed)
- Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:
- Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
- Patients with all stages of disease are considered eligible
- Patients who do not speak English can be eligible if accompanied by an institutional interpreter
- Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
Key exclusion criteria (1 listed)
- Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Follow-UpAlso: Active Follow-up, Clinical Signs Follow-up, CLSFUP, Follow UpReceive follow up | Other | Observational (medical chart review) |
| Medical Chart ReviewAlso: Chart ReviewReview of medical records | Other | Observational (medical chart review) |
Primary outcome
Disease characterization data
Time frame: through study completion, an average of 1 year
Information collected from retrospective and prospective review of medical records.
Patient treatment data
Time frame: through study completion, an average of 1 year
Information collected from retrospective and prospective review of medical records.
Patient outcome data
Time frame: through study completion, an average of 1 year
Information collected from retrospective and prospective review of medical records.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- University of Texas MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Cervical Large Cell Neuroendocrine Carcinoma
RecruitingPhase 1/2
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Melanoma, Medullary Thyroid Cancer
RecruitingPhase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Active, not recruitingPhase 2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Breast Cancer, Cholangiocarcinoma
Active, not recruitingPhase 1
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Urinary Bladder Cancer, Melanoma
Recruiting
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cancer Pain, Visceral Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Larissa A. Meyer principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cervical Large Cell Neuroendocrine Carcinoma and Cervical Neuroendocrine Carcinoma, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Larissa A. Meyer, MD (713-745-0973, lmeyer@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease characterization data (time frame: through study completion, an average of 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.